Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC; DOVE Investigators. Heeney MM, et al. N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021. Epub 2015 Dec 8. N Engl J Med. 2016. PMID: 26644172 Free article. Clinical Trial.
Definitions of the phenotypic manifestations of sickle cell disease.
Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, Johnson CS, Rogers ZR, Smith-Whitley K, Wang WC, Telen MJ; Investigators, Comprehensive Sickle Cell Centers. Ballas SK, et al. Among authors: heeney mm. Am J Hematol. 2010 Jan;85(1):6-13. doi: 10.1002/ajh.21550. Am J Hematol. 2010. PMID: 19902523 Free PMC article.
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T. Vichinsky E, et al. Among authors: heeney mm. Br J Haematol. 2011 Aug;154(3):387-97. doi: 10.1111/j.1365-2141.2011.08720.x. Epub 2011 May 19. Br J Haematol. 2011. PMID: 21592110 Free PMC article. Clinical Trial.
Platelet activation and inhibition in sickle cell disease (pains) study.
Frelinger AL 3rd, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, Michelson AD. Frelinger AL 3rd, et al. Among authors: heeney mm. Platelets. 2014;25(1):27-35. doi: 10.3109/09537104.2013.770136. Epub 2013 Mar 7. Platelets. 2014. PMID: 23469943
Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.
Styles L, Heiselman D, Heath LE, Moser BA, Small DS, Jakubowski JA, Zhou C, Redding-Lallinger R, Heeney MM, Quinn CT, Rana SR, Kanter J, Winters KJ. Styles L, et al. Among authors: heeney mm. J Pediatr Hematol Oncol. 2015 Jan;37(1):1-9. doi: 10.1097/MPH.0000000000000291. J Pediatr Hematol Oncol. 2015. PMID: 25493452 Clinical Trial.
Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC, Styles L, Heath LE, Zhou C, Jakubowski JA, Winters KJ, Brown PB, Rees DC, Heeney MM. Hoppe CC, et al. Among authors: heeney mm. Pediatr Blood Cancer. 2016 Feb;63(2):299-305. doi: 10.1002/pbc.25771. Epub 2015 Sep 24. Pediatr Blood Cancer. 2016. PMID: 26402148 Clinical Trial.
Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM, Hoppe CC, Rees DC. Heeney MM, et al. N Engl J Med. 2016 Jul 14;375(2):185-6. doi: 10.1056/NEJMc1603499. N Engl J Med. 2016. PMID: 27410930 No abstract available.
Sickle Cell Disease.
Smith ER, Heeney M, Scott RM. Smith ER, et al. N Engl J Med. 2017 Jul 20;377(3):304. doi: 10.1056/NEJMc1706325. N Engl J Med. 2017. PMID: 28727407 Free article. No abstract available.
95 results